<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536796</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CAT-CRE-2007/2</org_study_id>
    <nct_id>NCT00536796</nct_id>
  </id_info>
  <brief_title>Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets</brief_title>
  <official_title>Non-interventional Study Investigating How Effective Secondary Prevention Patients Are Treated to Their LDL-C Targets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia
      (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and
      rate of patients who are treated to target (which is &lt;100mg/dl for patients with high risk
      and &lt;70mg/dl for patients at very high risk) are screened (hospital-based specialists). The
      doctors therapy decisions after the screening and possible reasons for these decisions will
      be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are
      treated to their LDL-C target and to underline the importance of treating patients to their
      cholesterol targets.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cholesterol levels</measure>
    <time_frame>After 4 weeks</time_frame>
    <description>Cholesterol levels from high risk patients after 4 weeks of cholesterol-lowering drug therapy under target values</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">1096</enrollment>
  <condition>Hyperlipidemias</condition>
  <condition>Atherosclerosis</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>Carotid Stenosis</condition>
  <condition>Peripheral Vascular Diseases</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Patients at very high risk</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients at high risk</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients at medium risk</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients at low risk</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female secondary prevention patients with: coronary disease with event: acute
        coronary syndrome, status post MI, PTCA, CABG, angiographically verified), PAVK (min. IIb
        or S.p. revascularization), stroke/TIA, carotis-plaque (asymptomatic min. 70% or S.p.
        revascularization), Diabetes Mellitus (type I, II)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart
             disease, carotid stenosis, PVD, etc.) and/or diabetes who already receive
             cholesterol-lowering therapy

        Exclusion Criteria:

          -  Patients who do not receive cholesterol-lowering therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef Patsch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chair of the Austrian Atheroslerosis Society</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernhard Foger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Co-Chair of the Austrian Atheroslerosis Society</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rohrbach</city>
        <state>Upper Austria</state>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2007</study_first_submitted>
  <study_first_submitted_qc>September 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2007</study_first_posted>
  <last_update_submitted>October 29, 2014</last_update_submitted>
  <last_update_submitted_qc>October 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Need-to-treat</keyword>
  <keyword>NIS</keyword>
  <keyword>Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Carotid Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

